Unicycive Posts 65% EPS Gain in Q2
Unicycive Therapeutics (NASDAQ:UNCY), a clinical-stage biotechnology firm focused on kidney disease treatments, released its second-quarter results on August 14, 2025, for the period ended June 30. The most important news was the ongoing regulatory process for its lead compound and a shift in operational spending. Net loss per share (GAAP) came in at $(0.52). The quarter showed a marked reduction in research and development costs and a strategic increase in spending to support potential commercialization. Overall, the results reflected the company's efforts to address regulatory hurdles while maintaining financial flexibility for future product launches.
Source: Analyst estimates for the quarter provided by FactSet.
Unicycive Therapeutics develops innovative medicines to address unmet needs in kidney disease, targeting chronic kidney disease (CKD) and acute kidney injury (AKI). The company’s main focus is on oxylanthanum carbonate, a potential new oral phosphate binder for hyperphosphatemia, a condition faced by many patients on dialysis.
Source Fool.com
